Literature DB >> 11838851

The potential of ESSG spondyloarthropathy classification criteria as a diagnostic aid in rheumatological practice.

Elisa Muñoz Gomariz1, MazoAgustínCisnal del, Verónica Pérez Guijo, Alejandro Escudero Contreras, MaríadelCarmenMuñoz Villanueva, Eduardo Collantes Estévez.   

Abstract

OBJECTIVE: The European Spondylarthropathy Study Group (ESSG) criteria for the classification of spondyloarthropathies (SpA) were developed with the aim of unifying and facilitating international medical communication. We assessed the potential of ESSG criteria as a diagnostic aid for rheumatology practices in terms of sex and prevalence rate.
METHODS: Data from 2 similarly designed and developed studies conducted in France and Spain were examined. Data were obtained from 3,494 patients seen at rheumatology outpatient services (28 in each country). The sensitivity and specificity of each ESSG criterion (except the radiological one) were assessed in terms of sex and country. Patients were divided into 4 groups according to number of criteria present at the time of the study: Group I had neither inflammatory spinal pain (ISP) nor synovitis; Group 2 had ISP and/or synovitis; Group 3 ISP and/or synovitis plus one additional criterion; Group 4 ISP and/or synovitis plus more than one additional criterion. The predictive value was determined by using different prevalence rates.
RESULTS: A prevalence of 27.6% for male and 8.0% for female patients was found at Spanish services; prevalence in French services was 9.1% males and 3.2% females. No significant differences in sensitivity and specificity for each sex between French and Spanish individuals were detected; the overall sensitivity and specificity were similar for men and women. By contrast, there were differences between patients from the 2 countries regarding individual ESSG criteria; thus, inflammatory spinal pain and synovitis were less specific in the female and male Spanish patients, respectively, relative to the French patients.
CONCLUSION: ESSG criteria can be used meaningfully to aid diagnosis when the prevalence of SpA exceeds 10% and the patient meets more than one of the additional criteria, or when prevalence exceeds 30% and the patient meets only one additional criterion.

Entities:  

Mesh:

Year:  2002        PMID: 11838851

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  5 in total

1.  Late appearance and exacerbation of primary Raynaud's phenomenon attacks can predict future development of connective tissue disease: a retrospective chart review of 3,035 patients.

Authors:  Slavica Pavlov-Dolijanovic; Nemanja S Damjanov; Nada Z Vujasinovic Stupar; Goran L Radunovic; Roksanda M Stojanovic; Dragan Babic
Journal:  Rheumatol Int       Date:  2012-07-22       Impact factor: 2.631

Review 2.  Distinctions between diagnostic and classification criteria?

Authors:  Rohit Aggarwal; Sarah Ringold; Dinesh Khanna; Tuhina Neogi; Sindhu R Johnson; Amy Miller; Hermine I Brunner; Rikke Ogawa; David Felson; Alexis Ogdie; Daniel Aletaha; Brian M Feldman
Journal:  Arthritis Care Res (Hoboken)       Date:  2015-07       Impact factor: 4.794

3.  Comparison of performance of the Assessment of SpondyloArthritis International Society, the European Spondyloarthropathy Study Group and the modified New York criteria in a cohort of Chinese patients with spondyloarthritis.

Authors:  Ho Yin Chung; Chak Sing Lau; Ka Pik Wu; Woon Sing Wong; Mo Yin MOK
Journal:  Clin Rheumatol       Date:  2011-02-19       Impact factor: 2.980

4.  Clinical and Laboratory Predictors of Articular Disorders Among HIV-infected Patients Seen at Teaching Hospital Southeast Nigeria.

Authors:  C C Okwara; G Ozoh; B C Nwatu
Journal:  Ann Med Health Sci Res       Date:  2015 Nov-Dec

5.  External Validation and Evaluation of Adding MRI or Extended Myositis Antibody Panel to the 2017 EULAR/ACR Myositis Classification Criteria.

Authors:  Queenie Luu; Jessica Day; Alix Hall; Vidya Limaye; Gabor Major
Journal:  ACR Open Rheumatol       Date:  2019-08-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.